Anti-miR-33 antisense oligonucleotide

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment produced no difference in total plasma cholesterol or LDL cholesterol between treatment and control groups over 12 weeks, demonstrating that the HDL-raising effect is selective a

Effect: null; no difference between groups

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study